Khartis Therapeutics
Khartis Therapeutics Raises $50M Series B for Oral Immunology Medicines
Khartis Therapeutics announced $50M in Series B financing on August 13, 2026. Khartis Therapeutics raised a $50 million Series B led by Forge Life Science Partners to advance its oral IGF-1R inhibitor for thyroid eye disease.
Round details
The financing includes backing from Forge Life Science Partners, Longwood Fund, Alexandria Venture Investments, Foresite Capital, Lilly Asia Ventures, Nextech Invest. The company did not publish a valuation with the announcement.
- Round: Series B
- Capital announced: $50M
- Total funding reported: $95M
- Headquarters: San Diego, CA
How the company plans to use the capital
Khartis will use the financing to advance its lead program, an oral, selective IGF-1R inhibitor for thyroid eye disease, and to continue developing its broader pipeline of oral small molecule medicines targeting clinically validated immunology pathways.
Why this matters for GTM teams
Existing investors Foresite Capital, Lilly Asia Ventures and Nextech Invest took part in the round, which brought total capital raised to $95 million. Chief Scientific Officer Craig Murphy said existing thyroid eye disease treatments come with real safety tradeoffs.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Khartis Therapeutics Series B announcement.
Company Info
Investors (6)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started


